

Odesa National Medical University
Department of General and Clinical
Pharmacology and Pharmacognosy

PHARMACOLOGY OF DRUGS INFLUENCING
ON EFFERENT INNERVATION.

AGENTS INFLUENCING

ON CHOLINERGIC RECEPTORS

[CHOLINOMIMETICS, CHOLINOBLOCKERS]



NERVOUS SYSTEM

PERIPHERAL

CENTRAL

EFFERENT

AFFERENT


VEGETATIVE

SOMATIC

SYMPATHETIC

PARASYMPATHETIC


SCHEME ON NEURONAL TRANSMISSION




SITES OF N-CHOLINORECEPTORS


- **Central nervous system**
- **Vegetative ganglia**
- **Adrenal medulla**
- **Sinocarotid zone**
- **Skeletal muscles**

CHOLINERGIC SYNAPSIS





CLASSIFICATION OF CHOLINOMIMETICS

M-	N-	M-, N-	
		direct action	indirect (anticholinesterases)
<p>Pilocarpine Aceclidine</p>	 <p>Nico- rette Cytiton</p>	<p>Acetyl- choline Carbo- choline</p>	<p><i>reversible:</i> Neostigmine Physostigmine Galantamine Pyridostigmine <i>irreversible:</i> POC, insecticides</p>

ACTIONS OF M-CHOLINOMIMETICS

heart

«-» ino, «-» chrono,
«-» dromotropic

**blood
vessels**

dilation

bronchi

spasm

GIT

**peristaltics – increasing,
sphincters – relaxation,
secretion - increasing**

**urinary
bladder**

**detrusor – increasing,
sphincters – relaxation**



ACTIONS OF M-CHOLINOMIMETICS




glands

(sweat, lachrymal, salivary, bronchial) **increasing** secretion;



eye

miosis, spasm of accommodation, **increasing** of intraocular pressure



CNS

hyperkinesia



USES OF M-CHOLINOMIMETICS

indications:

- Glaucoma (*pilocarpine*)
- Atony, paralytic obstruction of intestine (*aceclidine*)
- Atony of urinary bladder (*aceclidine*)



contra-indications:


- Bronchial asthma
- Peptic ulcer of stomach
- Mechanic obstruction of intestine
- Bradyarrhythmia
- Epilepsy

ANTICHOLINESTERASES

Neostigmine, physostigmine, galantamine, pyridostigmine

ACTIONS

- **M-cholinomimetic effects**
- +
- **Neuro-muscular transmission – increasing**



INDICATIONS

- **Glaucoma (*physostigmine*)**
- **Atony of urinary bladder, atony and paralytic obstruction of intestine (*neostigmine*)**
- **Myasthenia, paralysis, paresis, polyomyelitis, after-trauma recovery period (*galantamine, neostigmine*)**
- **Decurarization (*galantamine, neostigmine*)**

ACUTE POISONING BY MUSCARINE

Symptoms:

- **CNS excitation** (hallucination)
- **bradycardia, atrio-ventricular blockage**

- **bronchospasm**
- **vomiting, diarrhea**
- **sweating, hypersalivation**
- **miosis, spasm of accommodation, lacrimation**



First aid:

I.V. administration of
antidote – **ATROPINE** (10-
15 mg !)



ACUTE POISONING BY POC

Symptoms:

- See muscarine poisoning +
- **Tonic-clonic** convulsions

First aid:



- ✓ **cholinesterase re-activators** – **aloxim, dipyroxim, isonitrosin**
- ✓ **administration of atropine**


Odesa National Medical University

Department of Pharmacology and Pharmacognosy

CHOLINERGIC

ANTAGONISTS

M-CHOLINOBLOCKERS



LOCALIZATION OF CHOLINOBLOCKERS ACTION


Direct action – reversible blockers of the receptors

M-, H- (central) (*cyclodol (trihexyphenidyl)*)

M-
(*atropine, belladonna preparations, scopolamine etc*)

M₁-
(*pirenzepine*)

H- (*ganglionic blockers, myorelaxants*)



M- or N-cholinoreceptors

PHARMACODYNAMICS OF M-CHOLINOBLOCKERS

together with **depression of parasympathetic tonus, raising of sympathetic tonus**

CNS (tertiary amines)

In therapeutic doses – **sedative**, in toxic – **excitation, hallucination, agitation, convulsions;**
↓ **tremor, vestibular disturbances**




heart (in moderate doses)

«+» **chronotropic** (especially in young people), **improvement of AV-conductivity;**
↑ **oxygen demand of myocardium**

blood

vessels in toxic doses – **vasodilation**



PHARMACODYNAMICS OF M-CHOLINOBLOCKERS



GIT

**peristaltic – decreasing,
sphincters – contraction,
secretion – decreasing**

urinary bladder


**detrusor – relaxation,
sphincters – contraction**




bronchi

dilation, decreasing of secretion

PHARMACODYNAMICS OF M-CHOLINOBLOCKERS



mydriasis,
paralysis of accommodation
(*cycloplegia, far sightness*), ↑
intraocular pressure,
photophobia, ↓ **secretion**



atropine (upto 12 days) > scopolamine (3-5 days) >
homatropine (15-20 hrs) > platyphyllin (5-6 hrs,
without cycloplegia) > tropicamid (2-6 hs)

glands

(*sweat, lachrymal, salivary,*
gastrointestinal, bronchial) ↓ **secretion,**
↑ **body temperature (small children !)**

Also possess weak local anesthetic and
analgesic actions

USES OF M-CHOLINOBLOCKERS

- Preanesthetic medication (*atropine*)
- Vagus hyperactivity at heart
- Bronchial asthma, chronic obstructive pulmonary disease (*ipratropium, tiotropim*)
- In ophthalmology with diagnostic (*platyphyllin, homatropine*) and treatment purpose (*atropine*)
- Peptic ulcer of stomach, hyperacidic gastritis (*pirenzepine*)
- Spasm of smooth muscles (*platyphyllin, metacin*)
- Diarrhea (*belladonna agents, atropine*)
- Motion sickness (*agents, containing scopolamine*)
- Parkinson disease (*central M-cholinoblockers - cyclodol*)
- Poisoning by muscarine, anticholinesterases (*atropine*)



M-CHOLINOBLOCKERS

Actions

Reduce tonus of smooth muscles of internal organs and inhibit secretion of exocrine glands; cause mydriasis and cycloplegia; increase intraocular pressure, cause tachycardia and central cholinolytic action

Therapeutic uses

Bronchial asthma, spasm of smooth muscles, stomach and duodenum ulcer, premedication, cardiac arrest, diagnostic and treatment of ocular diseases, motion sickness, Parkinson's disease, vomiting, nausea

Adverse effects

Dryness of mouth, tachycardia, constipation, attack of glaucoma



ACUTE POISONING BY ATROPINE

Symptoms:

- adults – **100 mg**, children – **10 mg** (2-3 belladonna berries)
- **CNS excitation** (hallucination, delirium, agitation), followed by **depression**
- **tachycardia**
- **mydriasis**
- **dry, warm and red skin and mucosa**
- **hyperthermia** (especially children < 2 years). Dose of atropine **2 mg** can be **lethal !**



First aid:

- ✓ **symptomatic**
- ✓ **Intravenous physostigmine** (1-4 mg for adults, 0,5-1 mg for children!)



GANGLIONIC BLOCKERS

- ✓ **short acting (15-20 min) – hygronium, arphonad**
- ✓ **intermediate acting (1-6 hrs) – benzo hexonium, pentamine, pachycarpin**
- ✓ **long acting (6-12 hrs) – pirilen**

PHARMACOKINETICS

Absorption: **quaternary** amines (benzo hexonium, pentamine, hygronium) **badly** absorbed in GIT ⇒ **I.V., I.M.** administration; **tertiary** amines (pirilen, pachycarpin) **well** ⇒ **+ oral** way

Distribution: **tertiary** well cross BBB ⇒ central effects (psychical disturbances, tremor etc); **quaternary** amines **don't** cross BBB

Excretion: mainly, through kidneys

GANGLIONIC BLOCKERS

PHARMACODYNAMICS

block of N-cholinoreceptors of vegetative ganglia, so-called "pharmacological denervation"

blood vessels: sharp hypotension, especially up-right (orthostatic collapse !) because of :

- ▶ depression of venous tonic innervations ⇒ dilation of veins ⇒ decreasing of cardiac preload
- ▶ depression of arterial innervations ⇒ dilation of arteries ⇒ ↓ BP
- ▶ Depression of central cardiac stimulation ⇒ ↓ cardiac output ⇒ unloading of left ventriculus

GANGLIONIC BLOCKERS

PHARMACODYNAMICS

heart: ↓ contractility, moderate tachycardia

GIT: peristaltics – ↓, sphincters – contraction,
secretion of gastric and intestinal glands – ↓

urinary and reproductive: urine retention, ↓ erection

uterus: stimulation of contractive activity
(pachycarpin)

eye: mydriasis, paralysis of accommodation
(cycloplegia, far sightness), ↑ intraocular pressure


CNS: tertiary – sedation, tremor, psychical
disturbances

***Практически все эти эффекты не нашли
клинического применения (одновременные
неконтролируемые нарушения сердечно-сосудистой
функции) и рассматриваются как отрицательные !***

GANGLIONIC BLOCKERS

THERAPEUTIC USES

- hypertonic crisis
- pulmonary edema
- moment-to-moment (artificial) hypotension during surgery
- delivery (pachycarpin)



OVERDOSING

- acute hypotension
- tachycardia
- unconsciousness
- dry warm skin



MYORELAXANTS (NEURO-MUSCULAR BLOCKERS)

- **Drugs relaxing the skeletal muscles**
 - **Peripheral** (curare-type)
 - **Central** (for treatment of spasticity): tranquilizers (diazepam), baclofen, etc.

Myorelaxants of peripheral action — the drugs relaxing the skeletal muscles due to depression of neuromuscular transmission at the level of postsynaptic membrane of the end plate

Classification

- ✚ **Nondepolarizing (competitive) action** — tubocurarine, pipecuronium bromide (arduan), pancuronium bromide, vecuronium bromide, etc.
- ✚ **Depolarizing action** — dithyline (succinylcholine, succametonium chloride, listenone)
- ✚ **Mixed action** — dioxonium

PHARMACODYNAMICS OF MYORELAXANTS


Nondepolarizing:

competitive blockade of N-cholinoceptors on postsynaptic membrane

of the skeletal muscles \Rightarrow removal of block by the anticholinesterase drugs (\uparrow Ach content)

acetylcholine (AC)

tubocurarine




N-cholinoceptors of the skeletal muscles

Depolarizing:

activate N-cholinoceptors (like Ach), causing prolong depolarization of postsynaptic membrane \Rightarrow \downarrow block of pseudochoolinesterase

Phase I — depolarization (muscular twitching)



Phase II — desensitization (muscle paralysis)



PHARMACODYNAMICS OF MYORELAXANTS

Skeletal muscles:

nondepolarising: during first 1–5 min there is muscle weakness, followed by muscles paralysis in the following order: first - muscles of the eyes, jaws, then extremities, trunk, diaphragm (breathing arrest); recovery appear in the reverse order

◆ ***depolarizing:***

phase I (within 1 min) — temporary fasciculation (muscular twitching), especially of the chest, stomach, following by

phase II — relaxation of muscles of the neck, extremities, face, throat, diaphragm

MYORELAXANTS APPLICATION

- **Relaxation of the muscles of larynx and throat** during intubation for the inhalation anaesthesia and artificial lung ventilation
- **Relocation** and reposition of bone fragments in case of fractures
- **Surgical operations** on the abdominal and chest organs under anaesthesia with artificial ventilation of lungs
- **Convulsions** in case of poisoning by substances which depress the respiratory center, in case of meningitis, cerebral and cranial traumas for transition to AVL
- **Spasticity with Parkinson disease**, encephalitis and other dysfunctions of the pyramidal and extrapyramidal system

MYORELAXANTS

Adverse effects

- **Bronchi:** *tubocurarine* — bronchial spasm
- **Electrolyte balance:** *dithyline* — hyperkalemia
- **Eyes:** *dithyline* — ↑ intraocular pressure
- **GIT:** *dithyline* — ↑ intragastric pressure ⇒ vomiting
- **Muscular pains in the postoperative period:** *dithyline* (in 20% of people)
- **Long-term block (> 2 hrs instead of 2–10 min) and apnoea:** *dithyline* in people with genetic insufficiency of cholinesterase
- **Interactions:** potentiation of action — by inhaled general anesthetics, antibiotics-aminoglycosides, by the low doses of locally anesthetics (high doses weaken block)

MYORELAXANTS DISTINCTIONS

Action	Competitive	Depolarizing
<i>Mechanism of action</i>	Competition with Ach	Steady membrane depolarization
<i>Interaction with Ach</i>	↓ Block	↑ Block
<i>Removal of block (decurarization)</i>	Anticholinesterase drugs (proserin)	Blood transfusion (pseudochoolinesterase)
<i>Loss of K⁺ by the muscle</i>	No	Present
<i>Fibrillations</i>	No	Marked (phase I)
<i>Penetration to the muscular tissue</i>	Does not penetrate	Penetrates deeply
<i>Anaesthesia influence</i>	Strengthens	Does not influence